EU to pilot new risk-based model for postmarket drug testing
This article was originally published in SRA
The EU Heads of Medicines Agencies has endorsed plans to test a new risk-based model for identifying human and veterinary medicinal products that could be subjected to laboratory testing in the post-authorization phase under ongoing surveillance testing programs1.
You may also be interested in...
Following the announcement in the US that ranitidine drugs must be withdrawn from the market, the European Medicines Agency told the Pink Sheet it would decide on the fate of these medicines in the EU after wrapping up its own inquiry.
EU drug industry federation, EFPIA, is concerned that an increase in protectionist trade measures by some countries could result in tit-for-tat policies that could hamper the global response to contain COVID-19.
Stay current on regulatory guidelines from around the world with Medtech Insight's Guidance Tracker. Sixty-nine guidance documents have been posted on the tracker since its last update.